Kisqali
Ribociclib tablets for breast cancer. It blocks the signals that tell cancer cells to divide, slowing their spread.
- Category
- Oncology Support
- Active ingredient
- Ribociclib
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 200mg
This listing uses Kisqali as a reference name. A generic equivalent is supplied; its exact brand and manufacturer are confirmed before supply.
Prescription and consultation requirements for Kisqali vary by destination and are determined by the fulfilment partner.
Kisqali details
- Condition
- Breast Cancer
- Therapeutic class
- Protein kinase inhibitors; Cyclin-dependent kinase inhibitors
- Pharmacological class
- Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Novartis Europharm Limited
- Storage instructions
- Store below 30°C. Keep in the original package to protect from moisture.
Contraindications
hypersensitivity to ribociclib or any excipient; hypersensitivity to peanut or soya
Precautions and warnings
neutropenia requiring regular complete blood count monitoring before and during treatment; hepatotoxicity requiring liver function test monitoring; qtc interval prolongation requiring ecg monitoring particularly with concomitant qt-prolonging medicines; interstitial lung disease and pneumonitis; severe cutaneous adverse reactions including stevens-johnson syndrome and drug reaction with eosinophilia and systemic symptoms; infections including pneumonia and sepsis; caution with strong cyp3a4 inhibitors requiring dose reduction; avoid concomitant use with strong cyp3a4 inducers; caution in patients with moderate to severe hepatic impairment; caution in patients with severe renal impairment; contains soya lecithin; embryo-foetal toxicity
Minor side effects
neutropenia; leukopenia; nausea; fatigue; diarrhoea; alopecia; vomiting; constipation; headache; back pain; rash; pruritus; decreased appetite; stomatitis; abdominal pain; dyspnoea; cough; pyrexia; dizziness; insomnia; anaemia; thrombocytopenia; urinary tract infection; peripheral oedema; arthralgia; asthenia; abnormal liver function tests; dysgeusia; epistaxis; dry skin; vertigo
Moderate side effects
febrile neutropenia; severe neutropenia; interstitial lung disease; pneumonitis; qtc prolongation; torsades de pointes; severe hepatotoxicity; hepatic failure; stevens-johnson syndrome; drug reaction with eosinophilia and systemic symptoms; pneumonia; sepsis; venous thromboembolism; acute kidney injury; tumour lysis syndrome
Serious side effects
signs of febrile neutropenia including fever, chills, sore throat, mouth ulcers, requires immediate medical attention; signs of interstitial lung disease including persistent dry cough, shortness of breath, chest pain, requires immediate medical attention; signs of hepatotoxicity including jaundice, dark urine, right upper abdominal pain, severe fatigue, requires immediate medical attention; signs of severe cutaneous reactions including widespread rash, blistering, facial swelling, fever, requires immediate medical attention; signs of qtc prolongation including palpitations, dizziness, fainting, seizures, requires immediate medical attention; signs of sepsis including high fever, confusion, rapid breathing, rapid heart rate, requires immediate medical attention
Patient summary
Ribociclib tablets for breast cancer. It blocks the signals that tell cancer cells to divide, slowing their spread.
Mechanism of action
Kisqali contains ribociclib, a medicine that belongs to a group called cyclin-dependent kinase 4 and 6 inhibitors. In breast cancer cells, certain proteins called cyclin-dependent kinases 4 and 6 help the cells grow and divide. Ribociclib blocks these proteins, which slows down or stops the cancer cells from multiplying. It is used in combination with hormone therapy medicines called aromatase inhibitors or fulvestrant, which work in a different way to starve the cancer cells of the hormones they need to grow.
Drug interactions
ketoconazole; itraconazole; voriconazole; posaconazole; clarithromycin; telithromycin; ritonavir; indinavir; nelfinavir; saquinavir; rifampicin; carbamazepine; phenytoin; st. john's wort; tamoxifen; quetiapine; pimozide; ondansetron; amiodarone; disopyramide; procainamide; sotalol; chloroquine; halofantrine; grapefruit juice; midazolam; alfentanil; fentanyl; ciclosporin; tacrolimus; everolimus; sirolimus; simvastatin; atorvastatin; rosuvastatin
Age restrictions
Safety and efficacy in paediatric patients below 18 years have not been established.
Pregnancy and breastfeeding
Pregnancy: Kisqali should not be used during pregnancy unless the clinical condition of the woman requires treatment. Women of childbearing potential must use effective contraception during treatment and for at least 21 days after the last dose. Breastfeeding: Should be discontinued during treatment and for at least 21 days after the last dose.
What you will receive
Kisqali is used here as a reference originator brand name to identify the medicine. We are not affiliated with the brand owner, and this listing does not offer the originator product.
- The supplied product is a generic equivalent containing Ribociclib, not the originator brand shown as the reference.
- The exact generic brand, manufacturer and dispatch location are confirmed based on the product, destination and available manufacturer or partner warehouse.
- Check the final product details at checkout before confirming an order.